In summary, PARP inhibitors demonstrate a very promising safety profile and anti-tumor efficacy in patients with BRCA1 or BRCA2-mutated platinum-sensitive ovarian cancer patients in both treatment and maintenance settings. Here, BRCA1 is linked to ovarian carcinoma.